Borstkanker Onderzoek Groep

2 in Phase 3

Quick facts

Phase 3 pipeline

Non-Steroidal Aromatase Inhibitor · Oncology
Inhibits the enzyme aromatase, which is involved in the production of estrogen.
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine · Oncology
This combination regimen uses multiple chemotherapy agents and an anti-angiogenic antibody to kill cancer cells through distinct mechanisms: microtubule stabilization, vascular disruption, DNA intercalation, and antimetabolite activity.

Phase 2 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Borstkanker Onderzoek Groep

What is Borstkanker Onderzoek Groep's pipeline?

Borstkanker Onderzoek Groep has 2 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include Non-Steroidal Aromatase Inhibitor, Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine.

Sector hub: All tracked pharma companies